JESSICA GARCIA-OTERO: Open Payments
NPI 1811505811 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,615 in 126 payments from 14 companies in 2025. Trend: 2023 $856 · 2024 $984 · 2025 $2,615
Food & beverage: $2,615
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $602 |
| Supernus Pharmaceuticals, Inc. | 24 | $446 |
| E.R. Squibb & Sons, L.L.C. | 23 | $441 |
| Alkermes, Inc. | 7 | $191 |
| Otsuka America Pharmaceutical, Inc. | 7 | $136 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $127 |
| Axsome Therapeutics, Inc. | 2 | $117 |
| Vanda Pharmaceuticals Inc. | 5 | $99 |
| Teva Pharmaceuticals USA, Inc. | 4 | $93 |
| Corium, LLC | 5 | $89 |
Products named: VRAYLAR, Qelbree, COBENFY, ARISTADA, REXULTI, CAPLYTA, Auvelity, FANAPT.
Industry payments across IL — which companies pay providers there.
